NewsBenzingaAlnylam e Regeneron affermano che i dati pubblicati sul New England Journal of Medicine riportano una riduzione fino all’80% del grasso epatico, mantenuta per 36 settimane dopo una singola dose di siRNA contro CIDEB in pazienti con MASLD. Alnylam e Regeneron affermano che i dati pubblicati sul New England Journal of Medicine riportano una riduzione fino all’80% del grasso epatico, mantenuta per 36 settimane dopo una singola dose di siRNA contro CIDEB in pazienti con MASLD. Benzinga 2026.11.10 15:02 (GMT+0) Open on Benzinga Other news Ramp in Talks to Raise at Least $1 Billion at Valuation of Up to $75 Billion How Everyday Investors Are Playing the Nvidia Drama Curve: Fee Conversion Contract Loses $38.2K in Attack, Disabled With Replacement Planned Alvotech (ALVO) Presents at UBS Global Biopharma Conference 2026 Transcript Nvidia Tops Sales Forecast After Huang's Resignation Bill Gates Has Earned $2.6 Billion in Dividends From a Landfill Stock the EPA Keeps Citing for Methane Leaks, and a Filing Shows He Just Bought 3.7M More Shares
Bill Gates Has Earned $2.6 Billion in Dividends From a Landfill Stock the EPA Keeps Citing for Methane Leaks, and a Filing Shows He Just Bought 3.7M More Shares